technology

Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Feb 16, 2017 BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial mar...
Feb 9, 2017 BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare Conference at 1:00 p.m. ET (10:00 a.m. PT) ...
Jan 2, 2017 BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 35th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT (7:00 p.m. ET) on Monday, Jan...
Nov 28, 2016 BOTHELL, Wash., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the initiation of PROMISE 2 (PRevention Of Migraine via Int...
Nov 1, 2016 BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthca...
Oct 27, 2016 Company Finalizes ALD403 Pivotal Program Design and Confirms Planned Initiation of PROMISE 2 Phase 3 Study in 2016 Top-Line ALD403 PROMISE 1 Phase 3 Data Expected in First Half of 2017  BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ...
Oct 20, 2016 BOTHELL, Wash., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its third quarter 2016 financial and operating results after the close of U.S. financial markets on&...
Oct 11, 2016 BOTHELL, Wash., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage company developing monoclonal antibody therapeutics, today announced the promotion of Larry Benedict to the position of Executive Vice President and Principal Accounting Officer. Mr. Benedict, who has served as Senior...
Sep 21, 2016 BOTHELL, Wash., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Nancy L. Boman, M.D., Ph.D. as senior vice president of regulatory affairs and pharmacovigilance. Dr. Boman wi...
Sep 15, 2016 BOTHELL, Wash., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine as well as preclini...
Page:
1
... NextLast
= add release to Briefcase